A study to investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in participants with suspected NASH.

Trial Identifier: D9230C00002
Sponsor: AstraZeneca
Start Date: March 2023
Primary Completion Date: March 2024
Study Completion Date: March 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation

Trial Locations